Mark A Socinski

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. doi request reprint Incorporating Immunotherapy Into the Treatment of Non-Small Cell Lung Cancer: Practical Guidance for the Clinic
    Mark A Socinski
    Co Leader, UPCI Lung Cancer Program, University of Pittsburgh Medical Center, Pittsburgh, PA Electronic address
    Semin Oncol 42:S19-28. 2015
  2. doi request reprint Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer
    M A Socinski
    Division of Hematology Oncology, University of Pittsburgh Cancer Institute, PA 15232, USA
    Ann Oncol 24:2390-6. 2013
  3. pmc Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines
    Mark A Socinski
    Division of Hematology Oncology, University of Pittsburgh, Pittsburgh, PA 15232, USA
    Chest 143:e341S-68S. 2013
  4. pmc A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer
    Mark A Socinski
    University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15232, USA
    Clin Cancer Res 19:3068-77. 2013
  5. doi request reprint Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial
    Mark A Socinski
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    J Clin Oncol 30:2055-62. 2012
  6. doi request reprint Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer
    M A Socinski
    University of Pittsburgh Medical Center, Division of Hematology Oncology, Pittsburgh, PA 15232, USA
    Ann Oncol 24:314-21. 2013
  7. doi request reprint Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial
    Mark A Socinski
    UPMC Cancer Pavilion, 5150 Centre Avenue, 5th Floor, Pittsburgh, PA 15232, USA
    J Clin Oncol 30:3953-9. 2012
  8. doi request reprint Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small ce
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, 3009 Old Clinic Building CB 7305, Chapel Hill, NC 27599 7305, USA
    J Thorac Oncol 3:250-7. 2008
  9. doi request reprint Late complications of high-dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer
    Carrie B Lee
    Division of Hematology Oncology, Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center at University of North Carolina at Chapel Hill, North Carolina, USA
    J Thorac Oncol 4:74-9. 2009
  10. doi request reprint Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer
    M Patricia Rivera
    Multidisciplinary Thoracic Oncology Group, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7248, USA
    Chest 135:1588-95. 2009

Collaborators

Detail Information

Publications68

  1. doi request reprint Incorporating Immunotherapy Into the Treatment of Non-Small Cell Lung Cancer: Practical Guidance for the Clinic
    Mark A Socinski
    Co Leader, UPCI Lung Cancer Program, University of Pittsburgh Medical Center, Pittsburgh, PA Electronic address
    Semin Oncol 42:S19-28. 2015
    ..Thus, physicians are presented with the challenge of appropriately identifying and managing these unfamiliar immune-related adverse events. ..
  2. doi request reprint Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer
    M A Socinski
    Division of Hematology Oncology, University of Pittsburgh Cancer Institute, PA 15232, USA
    Ann Oncol 24:2390-6. 2013
    ....
  3. pmc Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines
    Mark A Socinski
    Division of Hematology Oncology, University of Pittsburgh, Pittsburgh, PA 15232, USA
    Chest 143:e341S-68S. 2013
    ..Stage IV non-small cell lung cancer (NSCLC) is a treatable, but not curable, clinical entity in patients given the diagnosis at a time when their performance status (PS) remains good...
  4. pmc A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer
    Mark A Socinski
    University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15232, USA
    Clin Cancer Res 19:3068-77. 2013
    ..In this phase II study, we evaluated the activity and tolerability of ganetespib in previously treated patients with non-small cell lung cancer (NSCLC)...
  5. doi request reprint Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial
    Mark A Socinski
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    J Clin Oncol 30:2055-62. 2012
    ..This phase III trial compared the efficacy and safety of albumin-bound paclitaxel (nab-paclitaxel) plus carboplatin with solvent-based paclitaxel (sb-paclitaxel) plus carboplatin in advanced non-small-cell lung cancer (NSCLC)...
  6. doi request reprint Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer
    M A Socinski
    University of Pittsburgh Medical Center, Division of Hematology Oncology, Pittsburgh, PA 15232, USA
    Ann Oncol 24:314-21. 2013
    ..This analysis evaluates safety and efficacy in elderly (≥ 70 years old) versus younger patients enrolled in a phase III advanced non-small-cell lung cancer (NSCLC) trial...
  7. doi request reprint Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial
    Mark A Socinski
    UPMC Cancer Pavilion, 5150 Centre Avenue, 5th Floor, Pittsburgh, PA 15232, USA
    J Clin Oncol 30:3953-9. 2012
    ..Bevacizumab and erlotinib have been shown to improve survival in stage IV non-small-cell lung cancer (NSCLC). This phase I/II trial was designed to incorporate these agents with induction and concurrent chemoradiotherapy in stage III NSCLC...
  8. doi request reprint Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small ce
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, 3009 Old Clinic Building CB 7305, Chapel Hill, NC 27599 7305, USA
    J Thorac Oncol 3:250-7. 2008
    ..We investigate the tolerability of gefitinib in combined modality therapy in combination with three-dimensional thoracic conformal radiation therapy (3-dimensional TCRT)...
  9. doi request reprint Late complications of high-dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer
    Carrie B Lee
    Division of Hematology Oncology, Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center at University of North Carolina at Chapel Hill, North Carolina, USA
    J Thorac Oncol 4:74-9. 2009
    ..Dose escalation of radiotherapy is one strategy used to improve locoregional control and survival, but it increases the risk of both early and late treatment related toxicities...
  10. doi request reprint Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer
    M Patricia Rivera
    Multidisciplinary Thoracic Oncology Group, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7248, USA
    Chest 135:1588-95. 2009
    ....
  11. ncbi request reprint Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, CB 7305, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 22:4341-50. 2004
    ..Dose escalation using three-dimensional thoracic conformal radiation therapy (TCRT) is one strategy to improve local control and perhaps survival...
  12. doi request reprint Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and paclitaxel in unresectable stage IIIA/B non-small cell lung cancer
    Thomas E Stinchcombe
    Division of Hematology Oncology, Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
    J Thorac Oncol 3:1279-85. 2008
    ....
  13. doi request reprint Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105
    Mark A Socinski
    Lineberger Comprehensive Cancer Center, University of North Carolina Chapel Hill, NC 27599, USA
    J Clin Oncol 26:2457-63. 2008
    ..To evaluate 74 Gy thoracic radiation therapy (TRT) with induction and concurrent chemotherapy in stage IIIA/B non-small-cell lung cancer (NSCLC)...
  14. doi request reprint Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer
    Mark A Socinski
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    J Thorac Oncol 5:354-60. 2010
    ....
  15. ncbi request reprint Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer
    Daniel B Fried
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, Department of Epidemiology, School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    J Clin Oncol 22:4837-45. 2004
    ..In addition, we assessed the impact of radiation fractionation and chemotherapeutic regimen on timing...
  16. doi request reprint Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
    Patrick J Roberts
    Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7295, USA
    J Clin Oncol 28:4769-77. 2010
    ....
  17. pmc A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients
    Janine M Davies
    Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hil, USA
    Lung Cancer 71:151-5. 2011
    ..Sorafenib has demonstrated single agent activity in non-small cell (NSCLC) and small cell lung cancer (SCLC). Carboplatin/pemetrexed (CbP) and cisplatin/etoposide (PE) are commonly used in the treatment of these diseases...
  18. ncbi request reprint Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, 27599, USA
    Cancer 95:1265-73. 2002
    ..The authors sought to determine the activity of second-line, low-dose, weekly paclitaxel in patients with NSCLC who failed first-line chemotherapy with carboplatin plus paclitaxel...
  19. doi request reprint A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancer
    Thomas E Stinchcombe
    Division of Hematology Oncology, Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7, USA
    J Thorac Oncol 6:1569-77. 2011
    ..Single-agent gemcitabine is a standard of care for elderly patients with advanced non-small cell lung cancer, but novel therapies are needed for this patient population...
  20. ncbi request reprint A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer
    Thomas E Stinchcombe
    Department of Hematology Oncology, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    Lung Cancer 52:305-11. 2006
    ..The role of double agent therapy in this patient population is an area of investigation...
  21. ncbi request reprint Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer
    Thomas A Hensing
    Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
    Lung Cancer 47:253-9. 2005
    ..Factors increasing the likelihood of second-line therapy include high performance status, female gender and non-squamous histology, while early termination of first-line therapy decreased the likelihood of further therapy...
  22. pmc Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
    J Thorac Oncol 3:521-6. 2008
    ..This trial was designed to determine the maximum tolerated dose and dose limiting toxicities (DLT) of nab-paclitaxel in combination with gemcitabine...
  23. ncbi request reprint The emergence of a unique population in non-small cell lung cancer: systemic or loco-regional relapse following postoperative adjuvant platinum-based chemotherapy
    Mark A Socinski
    The Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    Semin Oncol 33:S32-8. 2006
    ....
  24. doi request reprint A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer
    Thomas E Stinchcombe
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, Physician s Office Building, 3rd Floor, Chapel Hill, NC 27599 7305, USA
    J Thorac Oncol 8:443-51. 2013
    ..We performed an exploratory, blinded, retrospective analysis of plasma or serum samples collected as part of the trial to investigate the ability of VeriStrat (VS) to predict treatment outcomes...
  25. pmc Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, CB 7305, Chapel Hill, NC 27599, USA
    J Clin Oncol 26:650-6. 2008
    ....
  26. ncbi request reprint High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial
    Julian G Rosenman
    Department of Radiation Oncology, Lineberger Comprehensive Cancer Center of the University of North Carolina University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA
    Int J Radiat Oncol Biol Phys 54:348-56. 2002
    ..The median survival of 24 months, 3-year survival rate of 38%, and the high dose of radiation used justified a critical analysis of the technical and clinical components of this trial...
  27. doi request reprint The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    J Thorac Oncol 3:145-51. 2008
    ..Carboplatin (C) is better tolerated than cisplatin, and carboplatin-based adjuvant therapy may have better chemotherapy compliance...
  28. ncbi request reprint A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer
    Heidi H Gillenwater
    The Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    Cancer Invest 23:511-9. 2005
    ..The purpose of this Phase I trial was to determine the maximally tolerated systemic exposure (MTSE) of topotecan in combination with carboplatin and etoposide...
  29. doi request reprint Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 27:5255-61. 2009
    ..This phase II trial, AVF3752g (PASSPORT), specifically addressed bevacizumab safety (incidence of grade > or = 2 CNS hemorrhage) in patients with NSCLC and previously treated brain metastases...
  30. doi request reprint Considerations for second-line therapy of non-small cell lung cancer
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 3009 Old Clinic Building CB 7305, Chapel Hill, North Carolina 27599 7305, USA
    Oncologist 13:28-36. 2008
    ..Several new agents have shown activity in phase II trials, and may be integrated into second-line therapy as single agents or in combination with current agents in the future...
  31. pmc Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung Cancer
    Jared M Weiss
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC Electronic address
    Clin Lung Cancer 17:128-32. 2016
    ..Patients with history of never or light smoking might derive greater benefit from these therapies...
  32. ncbi request reprint Seeking a home for a PET, part 2: Defining the appropriate place for positron emission tomography imaging in the staging of patients with suspected lung cancer
    Frank C Detterbeck
    Division of Cardiothoracic Surgery, Department of Surgery, Members of the Multidisciplinary Thoracic Oncology Program, University of North Carolina, Chapel Hill, NC, USA
    Chest 125:2300-8. 2004
    ..It is unclear and controversial whether a biopsy is needed in patients with clinical stage II lung cancer who have no PET uptake in the mediastinum...
  33. ncbi request reprint The role of induction therapy for resectable non-small cell lung cancer
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    Drugs 67:321-32. 2007
    ..The toxicity, efficacy and proper selection of patients for induction therapy, particularly induction chemoradiotherapy, will be assessed in ongoing and future clinical trials...
  34. doi request reprint The impact of local and regional disease extent on overall survival in patients with advanced stage IIIB/IV non-small cell lung carcinoma
    Daniel S Higginson
    Department of Radiation Oncology, University of North Carolina, Chapel Hill, North Carolina 27599 7512, USA
    Int J Radiat Oncol Biol Phys 84:e385-92. 2012
    ..The results have implications regarding the selection of patients for whom palliative thoracic radiation therapy may be of most benefit...
  35. ncbi request reprint Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: evolving role of dose-escalated conformal (3-dimensional) radiation therapy
    Carrie B Lee
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC 27599, USA
    Clin Lung Cancer 8:195-202. 2006
    ..Further well-designed clinical trials that examine RT dose escalation, improved tumor targeting, altered fractionation, and incorporation of biologic agents are crucial for progress in this disease...
  36. doi request reprint The current status and evolving role of sunitinib in non-small cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599 7305, USA
    J Thorac Oncol 3:S119-23. 2008
    ..Results of these trials are eagerly awaited and will help define the role of sunitinib in the therapeutic approach to NSCLC...
  37. pmc PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB o
    Jyoti D Patel
    Jyoti D Patel, Northwestern University Philip Bonomi, Rush University Medical Center, Chicago, IL Mark A Socinski, University of Pittsburgh, Pittsburgh, PA Edward B Garon, University of California at Los Angeles, Los Angeles, CA Craig H Reynolds, US Oncology Research, Ocala, FL David R Spigel, Sarah Cannon Research Institute Tennessee Oncology, Nashville, TN Mark R Olsen, Tulsa Cancer Institute, Tulsa, OK Robert C Hermann, Northwest Georgia Oncology Centers, Marietta, GA Robert M Jotte, Rocky Mountain Cancer Centers, Denver, CO Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR Donald A Richards, US Oncology Research, Tyler, TX Susan C Guba, Jingyi Liu, Bente Frimodt Moller, and William J John, Eli Lilly, Indianapolis, IN Coleman K Obasaju and Eduardo J Pennella, Department of Chemistry
    J Clin Oncol 31:4349-57. 2013
    ....
  38. doi request reprint Pemetrexed in relapsed small-cell lung cancer and the impact of shortened vitamin supplementation lead-in time: results of a phase II trial
    Mark A Socinski
    University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599 7305, USA
    J Thorac Oncol 3:1308-16. 2008
    ..We undertook a phase II trial to assess the efficacy and safety of single-agent pemetrexed (P) in relapsed small-cell lung cancer (SCLC) patients...
  39. ncbi request reprint The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel
    Thomas A Hensing
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    Cancer 98:779-88. 2003
    ....
  40. doi request reprint Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599 7305, USA
    J Thorac Oncol 5:1963-9. 2010
    ..This trial assessed pemetrexed-carboplatin ± enzastaurin to docetaxel-carboplatin in advanced non-small cell lung cancer...
  41. doi request reprint A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program at Lineberger Comprehensive Cancer Center at the University of North Carolina, Physicians Office Building, 3rd Floor 170 Manning Drive, CB 7305, Chapel Hill, NC 27599 7305, USA
    Cancer Invest 28:208-15. 2010
    ..To investigate the activity of carboplatin and cetuximab in NSCLC...
  42. doi request reprint Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer
    Mark A Socinski
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    J Clin Oncol 27:4787-92. 2009
    ....
  43. ncbi request reprint Beliefs among physicians in the diagnostic and therapeutic approach to non-small cell lung cancer
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    J Thorac Oncol 2:819-26. 2007
    ..Physicians' beliefs and practice patterns may differ significantly from established guidelines. We conducted a survey to assess and compare physician beliefs against the evidence-based guidelines...
  44. pmc Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation
    Matthew D Wilkerson
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
    PLoS ONE 7:e36530. 2012
    ..Patients may have incurred different mutations and alterations that led to the different subtypes. We hypothesized that the LAD molecular subtypes co-occur with distinct mutations and alterations in patient tumors...
  45. ncbi request reprint Current and evolving treatment options for limited stage small cell lung cancer
    Carrie B Lee
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, 27599, USA
    Curr Opin Oncol 18:162-72. 2006
    ..Several targeted agents have also been evaluated. This review will highlight the data that have greatly impacted on the standard of limited stage small cell lung cancer care...
  46. ncbi request reprint Current approaches to advanced-stage non-small-cell lung cancer: first-line therapy in patients with a good functional status
    Thomas E Stinchcombe
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill 27599 7305, USA
    Clin Lung Cancer 7:S111-7. 2006
    ..Well-designed clinical trials with appropriate patient selection, as well as continued efforts in translational research and pharmacogenomics, are crucial for progress in this disease...
  47. ncbi request reprint Combined modality therapy for stage III non-small cell lung cancer
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599 7305, USA
    Oncologist 11:809-23. 2006
    ..Thus, continued development and participation in clinical trials is crucial to further improvements in the treatment of patients with stage III disease...
  48. doi request reprint Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599 7305, USA
    Oncologist 13:933-44. 2008
    ..Results of recent gefitinib trials have been provocative, and suggest a role for gefitinib in the treatment of advanced NSCLC...
  49. pmc Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors
    Thomas E Stinchcombe
    Department of Hematology Oncology, Developmental Therapeutics Group Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
    Cancer Chemother Pharmacol 60:759-66. 2007
    ..The purpose of this study was to determine the maximum tolerated dose (MTD) of ABI-007, on three different schedules in combination with carboplatin...
  50. doi request reprint Current treatments for advanced stage non-small cell lung cancer
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    Proc Am Thorac Soc 6:233-41. 2009
    ..Despite the improvements in care and number of therapeutic agents available, the survival for patients with advanced-stage NSCLC remains modest; novel approaches are required and participation in clinical trials should be encouraged...
  51. ncbi request reprint Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status
    Thomas E Stinchcombe
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, 27599, USA
    Lung Cancer 51:237-43. 2006
    ....
  52. ncbi request reprint A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer
    Mark A Socinski
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    J Thorac Oncol 5:852-61. 2010
    ..This nonrandomized study aimed to identify the optimal dose of every-3-week (q3w) and weekly nab-paclitaxel plus q3w carboplatin as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) for a phase 3 trial...
  53. ncbi request reprint Phase II trial of paclitaxel, ifosfamide, and carboplatin in extensive-stage small cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, and US Oncology, Houston, TX, USA
    Lung Cancer 40:91-7. 2003
    ..This regimen has a tolerable toxicity profile and a favorable and convenient administration schedule...
  54. ncbi request reprint Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone
    Celeste Lindley
    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7360, USA
    Am J Clin Oncol 28:270-6. 2005
    ....
  55. ncbi request reprint The evolving role of pemetrexed (Alimta) in lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Semin Oncol 32:S16-22. 2005
    ..A phase II trial of single-agent pemetrexed is under way in both sensitive- and refractory-relapsed small cell lung cancer. Given the activity and excellent tolerability of pemetrexed, further studies in lung cancer are warranted...
  56. ncbi request reprint Clinical issues in the management of non-small-cell lung cancer and the role of platinum-based therapy
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill 27599 7305, USA
    Clin Lung Cancer 5:274-89. 2004
    ..Trials under way will determine the future of adjuvant or induction chemotherapy in treating this patient population...
  57. ncbi request reprint Cytotoxic chemotherapy in advanced non-small cell lung cancer: a review of standard treatment paradigms
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    Clin Cancer Res 10:4210s-4214s. 2004
    ..Future research may improve outcomes through identifying prognostic markers of treatment response to both standard cytotoxic and newer "targeted" therapies...
  58. ncbi request reprint Does more aggressive therapy improve outcomes in the treatment of unresectable stage III non-small cell lung cancer?
    Julian G Rosenman
    Lineberger Comprehensive Cancer Center, University of South Carolina, 101 Manning Drive, Chapel Hill, NC 27514, USA
    Semin Oncol 32:S13-7. 2005
    ....
  59. ncbi request reprint Radiation-induced sarcoma after high-dose thoracic radiation therapy in non-small-cell lung cancer
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA
    J Clin Oncol 25:1621-3. 2007
  60. ncbi request reprint Duration of therapy in advanced, metastatic non-small-cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
    Clin Adv Hematol Oncol 1:33-8. 2003
    ..Prolonged therapy does not appear to improve survival and carries the risk of cumulative toxicity. Second-line therapy considered in those patients fit enough to receive it at the time of disease progression...
  61. doi request reprint Predicting the need for palliative thoracic radiation after first-line chemotherapy for advanced nonsmall cell lung carcinoma
    Daniel S Higginson
    Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC, USA
    Cancer 118:2744-51. 2012
    ....
  62. doi request reprint Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsets
    Juneko E Grilley-Olson
    Department of Medicine, Division of Hematology Oncology, and Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7295, USA
    Arch Pathol Lab Med 137:32-40. 2013
    ....
  63. pmc Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue 555, Pittsburgh, PA 15232, U S A
    Anticancer Res 33:4475-81. 2013
    ..A phase I trial consisting of panobinostat (a HDAC inhibitor), carboplatin and etoposide was conducted in patients with lung cancer...
  64. ncbi request reprint Management of unresectable stage III non-small cell lung cancer: the role of combined chemoradiation
    Shannon K Penland
    Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, USA
    Semin Radiat Oncol 14:326-34. 2004
    ..This article will review the current data regarding treatment of this heterogeneous group of patients. In addition, a brief summary of new molecular therapies and chemotherapeutics will be presented...
  65. ncbi request reprint Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer
    Mark A Socinski
    Lineberger Comprehensive Cancer Center, Multidisciplinary Thoracic Oncology Program, University of North Carolina at Chapel Hill, Chapel Hill 27599, USA
    J Clin Oncol 24:4840-7. 2006
    ....
  66. pmc Personalizing therapy in advanced non-small cell lung cancer
    Liza C Villaruz
    Lung and Thoracic Malignancies Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
    Semin Respir Crit Care Med 34:822-36. 2013
    ..This review outlines the state of personalized lung cancer therapy as it pertains to individual NSCLC genotypes. ..
  67. ncbi request reprint Chemotherapeutic management of stage IV non-small cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, CB 7305, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Chest 123:226S-243S. 2003
    ..In addition, this awareness will allow them to make referrals, when appropriate, to physicians who are trained in the administration of chemotherapy and the management of patients undergoing such therapy...
  68. ncbi request reprint Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Cancer 95:1520-7. 2002
    ..This Phase II multicenter, open-label, single-arm study evaluated the efficacy and safety of a three-drug combination of irinotecan (CPT-11), paclitaxel, and carboplatin in advanced nonsmall cell lung carcinoma (NSCLC)...